瑞聯新材(688550.SH):大荔瑞聯可轉債項目因為實控人認定的原因仍處於中止狀態,等到實控人狀態穩定後公司會積極推進恢復申請工作
格隆匯9月11日丨瑞聯新材(688550.SH)接受特定對象調研時,有投資者問:大荔兩個工廠的建設規劃如何?
答:大荔瑞聯可轉債項目因為實控人認定的原因仍處於中止狀態,等到實控人狀態穩定後公司會積極推進恢復申請工作。大荔海泰完全用自有資金建設,項目的計劃總投資金額4.9億元,首期項目投資金額8300萬元(不含取得土地的費用),本項目建成後能夠滿足未來對於特定危險化學品和部分產品對產線、設備、安全、環保等專業生產的要求,從而擴大公司產品線和產品種類。預計建設週期12個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.